https://www.iongenomics.bio/p/illumina-q2-clinical-sequencing-strongIon Genomicsen2026-07-30T22:10:05+00:00Illumina Q2: Clinical Sequencing, Strong Instrument Sales Drive 10 Percent Revenue Growthhttps://www.iongenomics.bio/p/ultima-genomics-lands-baseclear-asIon Genomicsen2026-07-30T19:40:09+00:00Ultima Genomics Lands BaseClear as First European Certified Service Providerhttps://www.iongenomics.bio/p/adaptive-biotechnologies-mrd-testingIon Genomicsen2026-07-30T16:44:31+00:00Adaptive Biotechnologies MRD Testing Drives Q2 Revenue Growthhttps://www.iongenomics.bio/p/10x-genomics-continues-clinical-pushIon Genomicsen2026-07-29T20:53:59+00:00 10x Genomics Continues Clinical Push With Swiss Cancer Collab: Newsletter July 29, 2026https://www.iongenomics.bio/p/neogenomics-q2-revenues-rise-11-percentIon Genomicsen2026-07-29T20:32:14+00:00NeoGenomics Q2 Revenues Rise 11 Percent, Company Raises Full-Year Guidancehttps://www.iongenomics.bio/p/10x-genomics-partners-with-swissIon Genomicsen2026-07-29T17:44:39+00:0010x Genomics Partners With Swiss Hospital to Find Biomarkers Predicting Cancer Treatment Response